Eris Lifesciences on Tuesday announced the acquisition of the trademark for anti-diabetes novel drug Zomelis for $13 million, the company said in a release. Zomelis, the common name for which is vildagliptin, is used to treat type 2 diabetes, and is the first innovator pharmaceutical product trademark acquisition by Eris Lifesciences. Our inorganic growth strategy continues as we explore good …
